# Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer

> **NCT04425681** · PHASE2 · UNKNOWN · sponsor: **Second Affiliated Hospital of Nanchang University** · enrollment: 20 (estimated)

## Conditions studied

- Leptomeningeal Metastasis
- Non-small Cell Lung Cancer
- EGFR Activating Mutation

## Interventions

- **DRUG:** Osimertinib
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT04425681
- **Lead sponsor:** Second Affiliated Hospital of Nanchang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10-01
- **Primary completion:** 2020-07-01
- **Final completion:** 2021-06-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04425681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04425681, "Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04425681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*